Tapinarof
Brand names: Vtama · Active ingredient: Tapinarof
In short: VTAMA® cream is indicated for the topical treatment of plaque psoriasis in adults. VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
What is Tapinarof used for?
VTAMA® cream is indicated for the topical treatment of plaque psoriasis in adults.
VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
Tapinarof dosage
Apply a thin layer of VTAMA cream to affected areas once daily.
Wash hands after application, unless VTAMA cream is for treatment of the hands.
VTAMA cream is not for oral, ophthalmic, or intravaginal use.
How to take Tapinarof — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Administration Instructions
Instruct patients to apply VTAMA cream once daily to affected skin lesions only and avoid unaffected areas of skin.
Advise patients to wash hands after application unless VTAMA cream is for treatment of the hands.
Advise patients that VTAMA cream is for external use only.
Dist. by: Organon LLC, a subsidiary ofORGANON & Co.,Jersey City, NJ 07302, USA
For patent information: www.organon.com/our-solutions/patent/
vIGA-AD is the trademark of Eli Lilly and Co.
© 2025 Organon group of companies. All rights reserved.
uspi-og0505-cr-2505r000
Warnings & precautions
Do not take this medicine if: None.
Tapinarof side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Plaque Psoriasis Clinical Trials
In two randomized, double-blind, multicenter, vehicle-controlled clinical trials (PSOARING 1 and PSOARING 2), 1025 adults with plaque psoriasis were treated with VTAMA cream or received vehicle cream once daily for up to 12 weeks.
Subjects ranged in age from 18 to 75 years, with an overall median age of 51 years. The majority of subjects were White (85%) and male (57%); and 85% identified as non-Hispanic or Latino.
Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with VTAMA cream, and for which the rate exceeded the rate for vehicle. …
About this medicine
VTAMA (tapinarof) cream contains tapinarof as the active ingredient. Tapinarof is an aryl hydrocarbon receptor agonist.
Tapinarof is a white to pale brown powder. Chemically, tapinarof is 3, 5-dihydroxy-4-isopropyl-trans-stilbene, also known as (E)-2-isopropyl-5-styrylbenzene-1,3-diol, with the empirical formula C17H18O2, a molecular weight of 254.32, and the following structural formula.
Each gram of VTAMA cream for topical use contains 10 mg of tapinarof in a white to off-white cream. VTAMA cream also contains the following inactive ingredients: benzoic acid, butylated hydroxytoluene, citric acid monohydrate, diethylene glycol monoethyl ether, edetate disodium, emulsifying wax, medium-chain triglycerides, polyoxyl 2 stearyl ether, polyoxyl 20 stearyl ether, polysorbate 80, propylene glycol, purified water, and sodium citrate dihydrate.
How it works: Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown. Pharmacodynamics of VTAMA cream are unknown.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9309d20f-8cd4-4c96-93fa-7f730e83c7ab. Read the full official label on DailyMed.
Related medicines
Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab